Niemann-Pick Disease Type C Market Size
The Global Niemann-Pick Disease Type C (NPC) market reached US$ 9.00 million in 2024 to US$ 203.69 Million in 2025 and is expected to reach US$ 1850.04 Million by 2035, growing at a CAGR of 24.5% during the forecast period of 2026-2035.
Key Takeaways
- The global NPC market is projected to grow strongly, reaching USD 1850.04 Million by 2035.
- Market growth is driven by recent approvals of MIPLYFFA and AQNEURSA for NPC treatment.
- Arimoclomol, marketed as MIPLYFFA, is expected to dominate due to first-mover advantage.
- North America leads the market due to higher diagnosis rates and early drug availability.
- High treatment cost remains a major restraint, limiting access in low-income regions.
Executive Summary
Niemann-Pick Disease is a rare type of lysosomal storage disease (LSD) characterized by the deficiency of the acid sphingomyelinase enzyme that plays a crucial role in the hydrolysis of sphingomyelin to ceramide and phosphocholine. As a result of this enzyme deficiency, sphingomyelin, which plays a crucial role in cell membrane function, accumulates in the lysosomes of macrophages present across various organs such as the spleen, liver, lungs, and brain. This accumulation results in splenomegaly, hepatomegaly, cytopenia, lung diseases, and neurological manifestations.
Niemann-Pick Disease is classified into 3 types, notably type A, type B, and type C. At present, two drugs have been approved for the treatment of type C disease, and research is ongoing to bring advanced therapies for the other types.
| Disease Type | Gene Mutation | Deficiency | Treatment | Epidemiology |
| Type A | SMPD1 | Acid Sphingomyelinase Deficiency (<1% of normal enzyme production) | No Approved Therapies | 1 in 250,000 Live Births |
| Type B | SMPD1 | Acid Sphingomyelinase Deficiency (~ 10% of normal enzyme production) | No Approved Therapies | 1 in 250,000 Live Births |
| Type C | NPC1 or NPC2 | Impaired Cholesterol Esterification | Arimoclomol (Miplyffa), Levacetylleucine (Aqneursa) | 1 in 115,000 Live Births |
Market Dynamics: Drivers & Restraints
Rising Novel Product Approvals and Development Activities
Niemann-Pick Disease Type C (NPC) is one of the rarest and most fatal types of lysosomal storage diseases. The incidence of NPC ranges from 1 in 100,000 live births to 1 in 130,000 live births. Up until the 1H of 2024, no specific therapies were approved for NPC, and disease management completely focused on symptomatic relief. However, in the 2H of 2024, two drugs were approved for the indication, which has revolutionized the NPC treatment landscape. These drugs are expected to penetrate various markets around the globe and are anticipated to address the high unmet needs among the diagnosed population.
For instance, on September 20, 2024, the U.S. Food and Drugs Administration approved arimoclomol with the brand name MIPLYFFA, manufactured by Zevra Therapeutics, Inc., for the treatment of adult and pediatric NPC patients above 2 years of age. The drug is indicated in combination with Miglustat for the treatment of neurological manifestations of NPC. As per Zevra, nearly 1800 NPC patients were present in the U.S. and Europe, with 300 diagnosed in the United States. Within a month of approval, 90 prescriptions were enrolled in the U.S., and Zevra is extending patient access in Europe through Early Access Programs (EAP) and is planning to reach 70 to 80 patients through this program.
On the other hand, within a short span of MIPLYFFA approval, the U.S. FDA also approved IntraBio Inc’s AQNEURSA (levacetylleucine) on September 25, 2024, for the treatment of Niemann-Pick Disease Type C (NPC) in the adult and pediatric population. Unlike MIPLYFFA, this drug is approved as monotherapy for the indication. This is another key milestone in the NPC treatment landscape.
These drugs are only recently approved, and they are yet to penetrate several markets across the globe, which is anticipated to happen in the forecast period, driving the overall market growth.
High- Cost of Approved Drugs May Restrain the Market Growth.
Miplyffa and Aqneursa have become revolutionary therapies in the NPC landscape, however, these drugs are highly expensive, which makes their adoption questionable, especially in patients with no insurance coverage. For instance, the cost of 1 Miplyffa capsule can range between US$ 466.24 to US$ 1,230.00 depending on the dosage prescribed. Considering these prices and a daily dosage, the annual cost of patients on Miplyffa treatment can range between US$ 510,542.41 to US$ 1,346,778.58. This can be a huge economic burden to patients living in low-to-middle-income countries.
Market Segmentation Analysis
The global Niemann-Pick Disease Type C (NPC) market is segmented based on drug, patient type, and region.
Arimoclomol (MIPLYFFA) in the drug segment is dominating the market.
Arimoclomol, sold under the brand name MIPLYFFA and manufactured by Zevra Therapeutics, is the first prescription medication approved for the treatment of Niemann-Pick Disease Type C (NPC). The drug is recommended for use in adult and pediatric patients above 2 years of age in combination with miglustat and is given at various doses three times a day based on the patient’s actual body weight. MIPLYFFA received marketing authorization from the U.S. FDA on September 20, 2024, and was commercially launched in the U.S. market on November 21, 2024. This drug has also received the orphan medicinal product designation from the European Commission, however, the approval is still pending. Although not approved in the European Market, Zevra is providing MIPYFFA to patients in Europe through an early access program. This reflects Zevra’s strong efforts to commercialize its products globally, giving it a competitive edge in the market. Zevra’s R&D, manufacturing, and investment capabilities further drive the higher sales gain for MIPLYFFA. As per DataM intelligence, MIPLYFFA is expected to gain a sales value of ~ 350 million by 2030.
Market Geographical Share
North America dominated the Niemann-Pick Disease Type C (NPC) market.
The factors contributing to the region's dominance include high diagnosis and treatment rates and the first availability of approved drugs.
As per Zevra Therapeutics Inc., the estimated population in the U.S. with NPC is approximately 900, of which 300 patients are currently diagnosed. This represents a diagnosis rate of 33% in the country, which is higher compared to other countries of the world. In combination with the high diagnosis rate, the revolutionary treatments Miplyffa and Aqneursa were first approved in the U.S. market. It means that the patient population in the country receives first access to these drugs, and the manufacturers sell them at higher prices and generate most of their revenue from the country. This is a major contributing factor to the North America market dominance.
In addition, the favorable yet stringent regulatory scenario in the U.S. and their involvement in supporting drug discovery in development is a key factor for manufacturers preferring the U.S. for their product development, launch, and commercialization. The U.S. FDA provides special designations to drugs that can accelerate their approval time and provide early market access. For instance, apart from Miplyffa and Aqneursa, the U.S. FDA has granted Orphan Drug Designation to Cyclo Therapeutics, Inc.’s Trappsol Cyclo, which is currently in phase III trials for NPC. This designation can enable the drug to undergo a priority review process and receive accelerated approval. Once this is approved, the country to get access is the U.S.
Hence, considering all the factors, the North American region is designated as a dominant region in the global Niemann-Pick Disease Type C (NPC) market.
Major Players
The major players in the Niemann-Pick Disease Type C (NPC) market are Zevra Therapeutics, IntraBio, and Johnson & Johnson Services, Inc., among others.
Key Developments
- On February 7, 2025, Cyclo Therapeutics, Inc. announced the positive preliminary data from its ongoing phase III trial of Trappsol Cyclo, which is designated for the treatment of Niemann-Pick Disease Type C (NPC)1 (NPC1). In 7 among 8 subject populations, Trappsol Cyclo has stabilized and improved the Clinical Global Impression – Severity (CGI-S) scale at 24 weeks, and CGI-S stabilization and improvement was seen in 6 among 7 subjects who received treatment for 48 weeks. The company anticipates interim 48-week data in H1 of 2025, after which regulatory submissions will be done for marketing authorization.
- Cyclo Therapeutics Advanced Trappsol Cyclo Phase III Clinical Development
Cyclo Therapeutics continued advancement of its Phase III clinical program for Trappsol Cyclo, targeting neurological manifestations of Niemann-Pick Disease Type C (NPC). The therapy remains one of the most closely watched late-stage candidates in the rare neurodegenerative disorder segment. - Gene Therapy Research Gains Momentum for NPC Treatment
Biopharmaceutical companies and academic institutions are increasingly exploring gene therapy approaches for NPC, focusing on correcting NPC1 and NPC2 gene mutations. Preclinical research is showing promising potential for long-term disease modification and neurological improvement. - Expanded Newborn Screening and Early Diagnosis Initiatives
Healthcare systems and rare disease organizations are increasing focus on early diagnosis and genetic screening programs for lysosomal storage disorders, including NPC. Earlier identification is expected to improve treatment outcomes and expand the addressable patient population. - Orphan Drug Designations and Regulatory Support Accelerate Development
Regulatory agencies including the U.S. Food and Drug Administration and European Medicines Agency continue providing orphan drug incentives, fast-track pathways, and rare pediatric disease support to encourage NPC therapy development. - Growing Investment in Rare Neurological Disease Therapeutics
Pharmaceutical and biotech companies are increasing investments in lysosomal storage disorders and rare neurodegenerative diseases, driven by advances in precision medicine, biomarker development, and targeted CNS drug delivery technologies.
Niemann-Pick Disease Type C Market Scope
| Metrics | Details | |
| CAGR | 24.5% | |
| Market Size Available for Years | 2023-2035 | |
| Estimation Forecast Period | 2026-2035 | |
| Revenue Units | Value (US$ Mn) | |
| Segments Covered | Drug | Arimoclomol (MIPLYFFA), Levacetylleucine (AQNEURSA), and Miglustat |
| Patient Type | Adult and Pediatric | |
| Regions Covered | North America, Europe, Asia-Pacific, South America, and Middle East & Africa | |
Why Purchase the Report?
- Pipeline & Innovations: Reviews ongoing clinical trials and product pipelines and forecasts upcoming pharmaceutical advancements.
- Type Performance & Market Positioning: Analyze product performance, market positioning, and growth potential to optimize strategies.
- Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
- Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
- Market Updates & Industry Changes: This covers recent regulatory changes, new policies, and emerging technologies.
- Competitive Strategies: Analyze competitor strategies, market share, and emerging players.
- Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
- Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
- Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
- Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient Type delivery.
- Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
- Post-market Surveillance: Uses post-market data to enhance product safety and access.
- Pharmacoeconomic & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.
The global melanoma therapeutics market report would provide approximately 45 tables, 46 figures, and 180 pages.
Target Audience
- Manufacturers: Pharmaceutical, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
- Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
- Technology & Innovation: R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
- Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
- Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
- Supply Chain: Distribution and Supply Chain Managers.
- Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
- Academic & Research: Academic Institutions.
